Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

ConclusionsDaridorexant at 50 mg is classified as a weak CYP3A4 inhibitor after single- and multiple-dose administration once daily at steady state. Daridorexant 50 mg did not induce CYP3A4 activity or inhibit CYP2C9 activity.Clinical Trial RegistrationThis trial (NCT05480488) was registered on 29 July, 2022.

http://link.springer.com/10.1007/s40268-024-00456-8

Source: Drugs in R&D - March 13, 2024 Category: Drugs & Pharmacology Source Type: research